12/11/2007 2:14:23 PM
ATLANTA--(BUSINESS WIRE)--MGI PHARMA, INC. (NASDAQ:MOGN), a biopharmaceutical company focused in oncology and acute care, today provided a summary of the Dacogen® (decitabine) for Injection presentations made during the American Society of Hematology (ASH) 49th Annual Meeting and Exposition. Dacogen was the subject of five oral presentations, 11 poster presentations, and four publications. A survival analysis of the five-day outpatient regimen of Dacogen in patients with myelodysplastic syndromes (MDS) and preliminary results from a multicenter, phase 2 study evaluating the five-day regimen of Dacogen in patients with de novo or secondary MDS were among the data presented. Data from a phase 2 trial evaluating Dacogen in older patients with acute myelogenous leukemia (AML) were also presented at the conference.
comments powered by